SCHEMBL5010426

SCHEMBL5010426

CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(CO)CC4)ccc3OCC)nc12

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 20/20 0.90
PDE3B Q13370 3/20 0.90
PDE3A Q14432 3/20 0.90
PDE2A O00408 1/20 0.85
ABCC4 O15439 1/20 0.85
ABCC5 O15440 1/20 0.85
PDE6D O43924 1/20 0.85
PDE8A O60658 1/20 0.85
PDE9A O76083 1/20 0.85
ABCB11 O95342 1/20 0.85
CYP3A4 P08684 1/20 0.85
HTR1A P08908 1/20 0.85
PDE6A P16499 1/20 0.85
PDE6G P18545 1/20 0.85
PDE4A P27815 1/20 0.85
ADORA2A P29274 1/20 0.85
ADORA1 P30542 1/20 0.85
ADRA1A P35348 1/20 0.85
PDE6B P35913 1/20 0.85
PDE6C P51160 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lodenafil SCHEMBL31202790 0.95 PDE5A (1.00) PDE5APDE3BPDE3APDE2AABCC4
Lodenafil SCHEMBL1058 0.95 PDE5A (1.00) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL30848678 0.94 PDE5A (0.95) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL29358004 0.94 PDE5A (1.00) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL17342850 0.94 PDE5A (1.00) PDE5APDE3BPDE3APDE2AABCC4
Sildenafil SCHEMBL3399278 0.93 PDE5A (0.95) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL21682504 0.92 PDE5A (0.88) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL7915874 0.92 PDE5A (0.88) PDE5APDE3BPDE3APDE2AABCC4
Sildenafil SCHEMBL1895 0.92 PDE5A (1.00) PDE5APDE3BPDE3APDE2AABCC4
Sildenafil SCHEMBL5683880 0.92 PDE5A (1.00) PDE5APDE3BPDE3APDE2AABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1315729-B1 COMPOUNDS IN THE FORM OF HOMODIMERIC OR HETERODIMERIC PRODRUGS; PROCESS FOR OBTAINING THESE PRODRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASES-MEDIATED DISEASES OR DYSFUNCTION CRISTALIA PROD QUIMICOS FARM (BR) 2008-01-09 EP disclosed
US-7148350-B2 Compounds in the form of homodimeric or heterodimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction CRISTALIA PROD.QUI.FARM. LTDA (BR) 2006-12-12 US disclosed